Quantum Genomics announces the publication of a new scientific report
PARIS, March 31, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company specializing in the development of a new class of drugs that directly target the brain to treat resistant/difficult-to-treat hypertension and heart failure, announced the publication of a new scientific article reporting the efficacy of its second drug candidate, QGC606, in an experimental model of heart failure in Canadian Journal of Cardiology.
This article, titled “QGC606, a best-in-class, orally active, centrally acting aminopeptidase A inhibitor prodrug for the treatment of heart failure after myocardial infarction,presents the results of a study conducted with QGC606 in mice following a myocardial infarction, in collaboration with the INSERM team led by Catherine Llorens-Cortes at the Collège de France and the team from the Institute of Biology of Paris-Sorbonne University directed by Prof. Onnik Agboulout. The article is available online at the journal’s website (Articles in press: Canadian Journal of Cardiology (onlinecjc.ca); DOI: 10.1016/j.cjca.2022.01.019).
The data reported in this article demonstrate the efficacy of oral treatment with QGC606 to improve cardiac function and reduce fibrosis, thus preventing the occurrence of heart failure after myocardial infarction, at a dose 6 times lower than firibastat. . The data show that the efficacy of QGC606 is also comparable to that of ramipril selected as the reference drug, but unlike ramipril, QGC606, like firibastat, does not affect blood pressure levels in mice.
“The experimental data obtained with this new product are particularly promising because they position QGC606 as a potential best in class product,” says Fabrice Balavoine, Vice-President Research & Development at Quantum Genomics. “This reinforces the results already obtained with firibastat and further validates the therapeutic benefit of cerebral aminopeptidase A inhibitors in the prevention of cardiac dysfunction after myocardial infarction. »
About quantum genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the brain aminopeptidase A inhibition (BAPAI) mechanism. It is the only company in the world to pursue this innovative approach directly targeting the brain, based on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr Catherine Llorens-Cortès at the Collège from France. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (in about 30% of patients it is poorly controlled, or even treatment failure), and heart failure (one out of two diagnosed patients dies within five years).
Based in Paris, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and is listed on the American market OTCQX (symbol: QNNTF).
To learn more, visit www.quantum-genomics.com or our Twitter and Linkedin accounts.